Kailera Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, null, 24.85, 385.7 ], "ebit_estimate": [ -473.5, -442.07, -604.43, -754.7, -674.5 ], "ebitda_estimate": [ -452, -511, -394, null, null ], "net_income_estimate": [ -458.17, -561.4, -590.43, -754.7, -674.5 ], "per_share_eps_estimate": [ -3.03, -3.24, -2.92, -4.18, -3.35 ], "eps_nri_estimate": [ -3.03, -4.15, -3.75, -3.35, -3.35 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 5.97, 2.38, 5.54, null, null ], "pretax_income_estimate": [ -458, -562.2, -591.13, -756.4, -675.9 ], "operating_cash_flow_per_share_estimate": [ -2.42, -2.83, -2, null, null ], "roa_estimate": [ -50.1, -62.7, -42.7, null, null ], "roe_estimate": [ -56.8, -77.9, -51.2, null, null ], "gross_margin_estimate": [ null, null, null, null, null ], "operating_cash_flow_estimate": [ -285.44, -333.8, -235.9, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -43.04, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -29.45, "future_eps_nri_estimate_growth": -43.04, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -48.44, "future_ebitda_estimate_growth": -33.15, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -54.26, "future_pretax_income_estimate_growth": -54.34, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ null, null, null, null, null, null, null, null ], "ebit_estimate": [ -120.5, -133, -144.8, null, null, null, null, null ], "ebitda_estimate": [ null, null, null, null, null, null, null, null ], "net_income_estimate": [ -119.5, -132.15, -143.8, null, null, null, null, null ], "per_share_eps_estimate": [ -0.74, -0.83, -0.92, null, null, null, null, null ], "eps_nri_estimate": [ -0.75, -0.88, -0.99, -1.19, -1.22, -1.21, -1.21, -1.2 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -119.5, -132.15, -143.8, null, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, null, null, null, null, null ], "long_term_growth_rate_mean": -43.04, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -29.45, "future_eps_nri_estimate_growth": -43.04, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -48.44, "future_ebitda_estimate_growth": -33.15, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -54.26, "future_pretax_income_estimate_growth": -54.34, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }